Products Ibalizumab was approved in the United States in 2018 and in the EU in 2019 (Trogarzo, TaiMed Biologics). Structure and properties Ibalizumab is a humanized IgG4 monoclonal antibody. It is produced by biotechnological methods. Unlike most antiviral agents, it is directed against an endogenous drug target rather than the virus. Effects Ibalizumab has antiviral … Ibalizumab
Products Lanadelumab was approved as an injectable in the US and EU in 2018 and in many countries in 2019 (Takhzyro). Structure and properties Lanadelumab is a recombinant human IgG1κ monoclonal antibody with a molecular mass of 146 kDa. It is produced by biotechnological methods. Effects The effects of lanadelumab (ATC B06AC05) are based on … Lanadelumab
Products Siltuximab was approved in many countries in 2014 as a powder for a concentrate for [infusion solution>infusion] (Sylvant). Structure and properties Siltuximab is a human murine chimeric monoclonal antibody that binds human interleukin-6 (IL-6). Effects Siltuximab (ATC L04AC11) has anti-inflammatory and immunosuppressive properties. It prevents binding of human interleukin-6 to IL-6 receptors. Indications For … Siltuximab
Products Aducanumab has been studied in phase III trials and is in the pre-approval phase. The drug is not yet commercially available. The trials were discontinued in March 2019. However, following a re-analysis, the company announced in October 2019 that it expected to file for approval. Apparently, a sufficiently high dose is required for an … Aducanumab
Products Avelumab was approved in the United States, the EU, and many countries in 2017 as a concentrate for the preparation of an infusion solution (Bavencio). Structure and properties Avelumab is a human IgG1λ monoclonal antibody against programmed cell death ligand 1 (PD-L1) with a molecular weight of 147 kDa. It is produced by biotechnological … Avelumab
